Background -The aspirin-induced bronchoconstriction in patients with aspirinsensitive asthma is caused by cysteinyl leukotriene release. The cellular source of the leukotrienes is unknown. The inflammatory cell infiltrate in bronchial biopsy samples from seven aspirin-sensitive asthmatic (ASA) subjects and eight non-ASA subjects before and after local challenge with lysine aspirin was therefore examined.
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Background -The aspirin-induced bronchoconstriction in patients with aspirinsensitive asthma is caused by cysteinyl leukotriene release. The cellular source of the leukotrienes is unknown. The inflammatory cell infiltrate in bronchial biopsy samples from seven aspirin-sensitive asthmatic (ASA) subjects and eight non-ASA subjects before and after local challenge with lysine aspirin was therefore examined.
Methods -Using flexible bronchoscopy, airway mucosal biopsy samples were taken and lysine aspirin solution was placed directly onto a carina of the contralateral lung. Twenty minutes later a second series of biopsy samples was taken from the site of the local endobronchial lysine aspirin challenge. The biopsy samples were double immunostained with a rabbit polyclonal antibody to the enzyme 5-lipoxygenase and monoclonal antibodies to mast cells (AA1), neutrophils (NP57), macrophages (EBMII), T lymphocytes (anti-CD3), and total (BMK13) and activated eosinophils (EG2). Results -A decrease in both absolute mast cell numbers staining with mast cell tryptase (AA1) and the percentage ofmast cells co-immunostaining with 5-lipoxygenase was seen in the ASA patients after lysine aspirin challenge compared with the non-ASA control group. There was also an increase in the numbers of activated eosinophils (EG2) in the ASA subjects compared with the non-ASA group. No changes were observed in the total numbers of macrophages (EBMIl), neutrophils (NP57), total eosinophils (BAK13), and T lymphocytes (anti-CD3) after challenge with lysine aspirin. Conclusions -The decrease in numbers of mast cells staining for tryptase and the increase in activated eosinophils after endobronchial challenge with lysine aspirin may represent degranulation ofthese cell types, and may be an early event associated with aspirin-sensitive reactions in ASA subjects. (Thorax 1996; 51:64-70) Keywords: aspirin-sensitive asthma, endobronchial lysine aspirin, mast cells, eosinophils.
Asthmatic patients with sensitivity to aspirin and other non-steroidal anti-inflammatory drugs are often corticosteroid dependent and have accompanying symptoms of rhinosinusitis including rhinorrhoea, nasal congestion, anosmia, loss of taste, and recurrent severe nasal polyposis.' Upon ingestion of aspirin or other cyclo-oxygenase inhibitors, these individuals have increased cysteinyl leukotriene release as detected in the urine,23 nasal lavage fluid,45
and bronchial lavage fluid6 which does not occur in aspirin-tolerant subjects. Inhibition of the synthesis or the action of cysteinyl leukotrienes by a 5-lipoxygenase inhibitor78 or leukotriene receptor antagonists9"' leads to inhibition of the fall in forced expiratory volume in one second (FEV,) and amelioration of the naso-ocular effects induced by aspirin in aspirin-sensitive patients, strongly supporting the involvement of cysteinyl leukotrienes in this form of asthma. Despite the evidence for the involvement of cysteinyl leukotrienes in aspirin sensitivity, their cellular source is unknown and there are no previous data on the nature of the inflammatory process in the airways of patients with aspirin-sensitive asthma.
We have already examined the basal inflammatory cell infiltrate in bronchial biopsy samples from 12 aspirin-sensitive asthmatic (ASA) subjects and eight non-ASA control individuals" and found no significant difference in the total number of cells staining for 5-lipoxygenase between the two groups. As a percentage of total 5-lipoxygenase immunostaining cells, there were significantly more mast cells and total eosinophils and significantly fewer total macrophages in the bronchial biopsy samples from ASA subjects than from non-ASA subjects. The numbers of neutrophils, T lymphocytes, and activated eosinophils were similar for the two groups. The increased numbers of eosinophils and mast cells identified in the bronchial tissue from ASA subjects may be the source(s) of the enhanced cysteinyl leukotriene production observed in these unique individuals.
In order to assess the nature of the cellular population following lysine aspirin provocation, we have now studied the inflammatory cell infiltrate and the cellular expression of 5-lipoxygenase in bronchial biopsy tissues from asthmatic subjects with aspirin sensitivity before and after endobronchial lysine aspirin challenge and have compared the results with those in control non-ASA individuals. 57  nBDP  3-76  104  25  0.35  2  F  56  BUD, S, T, IB  2-1  91  2-5  0 39  3  M  39  BDP, S, T, nBUD  4-11  109  2-5  +  1-01  4  M  56  BDP, S, IB, F  3-52  104  7-5  +  0-34  5  M  54  PRED, BUD, S, T  3-2  93  2-5  +  0-36  6  F  26  BDP, S  2-93  87  25  +  0-32  7  M  24  BUD, nBUD, S  3-08  81  1 25  0-32 Mean (SE) 44 6 (5-6) 3-24 (0 25) 95 6 (3-9) 9-5 (4-1) 0-44 (0-1) PRED = prednisolone; BDP = beclomethasone dipropionate; BUD = budesonide; n = nasal route; S = salbutamol; T = theophylline; IB = ipratropium bromide; F = fenoterol. made at each time point and the highest value was used. Lysine aspirin inhalation challenge was performed by the method of SchmitzSchumann and co-workers.'2 Lysine aspirin (Synthelabopharma, Lausanne, Switzerland), a powder containing 900 mg lysine acetylsalicylate and 100 mg glycine, was diluted in 5 ml water to produce a solution of 180 mg/ml (0-55 mol/1) lysine acetylsalicylate (equivalent to 100 mg/ml acetylsalicylic acid). This solution was diluted with sodium chloride to produce a range of increasing doubling concentrations from 1-25 mg/ml to 25 mg/ml (3-8 mmol/I to 76 1 mmol/l). Nebulised solutions of 1 ml lysme aspirin were administered at room temperature using a Heyer nebuliser (Carl Heyer GmbH, Bad Ems, Germany). Delivery of air to the nebuliser was regulated to an output of 8 1/min and under these conditions the nebuliser delivers droplets with a mass median aerodynamic diameter of 5,um. After baseline measurements of FEVI, the subjects inhaled the aerosol via a mouthpiece during normal tidal breathing. If the decrease in FEV, following nebulised normal saline was <10% the subjects underwent lysine aspirin challenge. Incremental doubling concentrations of lysine aspirin were used for bronchial challenge at 30 minute intervals, with FEV, measurements at 15 and 30 minutes until a fall in FEV, of at least 20% was achieved (threshold concentration of lysine aspirin). A fall in FEV, of between 10% and 20% was allowed to return to within 10% of baseline before further lysine aspirin administration. Further measurements of FEV, were continued for at least four hours after a positive reaction and salbutamol was administered if necessary.
BRONCHOSCOPY
Bronchoscopies were all performed at the same time of day (08.00 hours) and by the same individual in accordance with current working party guidelines.13 Thirty minutes before the procedure all patients received 1 25mg salbutamol by nebulisation. After premedication with 05 mg atropine intramuscularly, 10 mg diazepam orally, and topical preservative-free 2% lignocaine, a fibreoptic bronchoscope (Olympus model BF-IT20D, Tokyo, Japan) was inserted orally and two or three mucosal biopsy samples were taken using non-toothed forceps from a right middle or lower lobe segmental carina. Supplemental oxygen was supplied via a nasal cannula at 4 1/min throughout the procedure and pulse and arterial oxygen saturation were monitored using a pulse oximeter. After endobronchial challenge with lysine aspirin via the bronchoscope the instrument was removed. It was re-introduced 20 minutes later after additional local anaesthesia, if necessary. Further biopsy samples were taken from the sites of the endobronchial challenges in the left lung. All subjects were monitored clinically during and for four hours after the procedure with measurements ofFEV, and to allow recovery from the sedation.
ENDOBRONCHIAL LYSINE ASPIRIN CHALLENGE
One millilitre of a solution of lysine aspirin corresponding to the threshold concentration was drawn into a soft plastic catheter and introduced into the bronchoscope. The catheter tip was first positioned on the carina between the lingula and the upper division bronchus and then on the carina of the left upper lobe. At each of the two sites one drop (20 ,ul) of lysine aspirin solution, at the previously determined threshold concentration, was placed gently on the carina and dispersed by lateral movements of the instrument without touching the bronchial mucosa. In the non-ASA subjects the same protocol was followed but the maximum challenge concentration of 25 mg/ml lysine aspirin was used. No previous reports of endobronchial lysine aspirin challenge were available and we therefore performed the challenge in two ASA and two non-ASA subjects in preliminary studies, in the manner described above. Immunohistochemical analyses of the biopsy samples, carried out in a blinded manner, revealed that this dose of lysine aspirin elicited an apparent increase in the number of cells staining with 5-lipoxygenase in ASA subjects compared with baseline. There were no changes in the two control non-ASA biopsy samples.
ANTIBODIES
The antibody to the enzyme 5-lipoxygenase was a rabbit polyclonal (kindly donated by J Evans, Merck Frosst Laboratories, Dorval, Quebec, Canada) and used at a dilution of 1/ 1000. All the primary antibodies used for cell identification were mouse monoclonal IgG1 antibodies and comprised the following: AAl (Dako, High Wycombe, UK), a mast cell tryptase marker used at a dilution of 1/50; EBM 11 (Dako), a pan-macrophage marker recognising CD68 used at 1/100 dilution; anti-CD3 (Dako), a pan-T lymphocyte marker used at 1/50 dilution; NP57 (Dako), an anti-human neutrophil elastase antibody used at 1/600 dilution; BMK13 (Cymbus Bioscience Ltd, Chilworth, UK), a pan-eosinophil marker recognising major basic protein used at 1/40 dilution; EG2 (Kabi Pharmacia, Milton Keynes, UK) which detects secreted eosinophil cationic protein and therefore is a marker for activated eosinophils and was used at 1/100 dilution. The secondary antibodies were a goat anti-mouse alkaline phosphatase conjugated antibody (Sera-lab, Crawley Down, UK) and used at a dilution of 1/100, and a swine antirabbit biotinylated antibody used at a dilution of 1/200.
IMMUNOSTAINING
The bronchial biopsy samples were immediately mounted in OCT and snap frozen using isopentane (BDH) cooled down in liquid nitrogen (Bayer, Basingstoke, UK). The samples were stored at -80°C until further analysis. Sections 5,um thick were cut from frozen bronchial biopsy samples onto slides coated with 3-aminopropyltriethoxy-silane (Sigma, Dorset, UK) to improve adhesion. '4 The sections were cut from the centre of the biopsy sample to ensure as large a cross sectional area as possible for immunostaining. They were then fixed in acetone and stored at -70°C until used for immunohistochemistry. One section was examined for each cell marker. The biopsy samples were double immunostained using a rabbit polyclonal antibody to the enzyme 5-lipoxygenase concurrently with one monoclonal antibody to each cell type: neutrophils (NP57); macrophages (EBMl 1); total (BMK13) and degranulated eosinophils (EG2); mast cells (AA1), and T lymphocytes (anti-CD3). Immunohistochemical analysis was carried out using both indirect avidinbiotin complex and alkaline phosphatase antialkaline phosphatase techniques. Endogenous biotin activity was abolished by incubating the sections with 0-01% avidin for 10 minutes followed by 0 01% biotin for 10 minutes. Each section was then treated with 1 / 10 normal swine serum (Dako) for 10 minutes to block nonspecific sites. The section was then incubated with a mixture of the anti-5-lipoxygenase and one of each of the cell marker primary antibodies for 90 mintues at room temperature. This was followed by incubation with 1/200 biotinylated swine anti-rabbit and 1/100 alkaline phosphatase conjugated goat anti-mouse secondary antibody for 45 
Results

SUBJECTS
The baseline characteristics of the two groups of subjects are presented in tables 1 and 2. There were no significant differences in FEV, between the ASA and non-ASA subjects, and no statistical differences in peripheral blood eosinophil count were seen between the two groups. Four of the seven ASA subjects and six of the eight non-ASA subjects were skin prick test positive to the aeroallergens tested. Bronchoscopy, endobronchial lysine aspirin challenge, and bronchial biopsy were well tolerated by all individuals and there were no adverse effects.
CELL NUMBERS
After endobronchial challenge there was a decrease in mast cell numbers staining for mast cell tryptase in the ASA subjects challenged with lysine aspirin from 30 4 (I 1 1)/mm2 to 14 1 (8 6)/mm2, and this change was significantly different (p<005) from the change in the non-ASA subjects (fig 1, table 3 ).
The number of total eosinophils (BMK13) in the ASA group was 1 48-6 (28-1)/mm2 before and 171 (40)/mm2 after challenge with lysine aspirin, which did not represent a significant difference from the change in the non-ASA group. There was an increase in EG2 positive eosinophils in six of the seven ASA subjects after lysine aspirin challenge, whereas only one non-ASA subject demonstrated an increase in the numbers of EG2 positive cells after challenge. The change in the numbers of EG2 positive cells in the ASA group was significantly different from the non-ASA subjects (p<005). Compared with the non-ASA group, there was no significant change in numbers ofmacrophages, neutrophils, or T lymphocytes in the ASA group after challenge with lysine aspirin. 
CELLS STAINING FOR 5-LIPOXYGENASE
Before endobronchial challenge the total numbers ofcells immunostaining for 5-lipoxygenase in the bronchial bronchial biopsy samples from the seven ASA subjects were similar to those in biopsy samples from the non-ASA control subjects (fig 2) . After endobronchial challenge there was no significant change in the numbers of 5-lipoxygenase staining cells in the ASA subjects compared with the change in the non-ASA subjects. The percentage of 5-lipoxygenase positive cells co-immunostaining with the mast cell marker AA1 decreased from 14-7 (5-1)% to 5 (2 3)% in the ASA group after endobronchial lysine aspirin challenge which was significantly different (p<005) from the change in the non-ASA group (3A4 (3K1)% to 2-3 (1-0)%).
The percentage of 5-lipoxygenase positive cells co-immunostaining for eosinophils (BMK13) was not significantly different between the ASA and non-ASA groups. However, the percentage of 5-lipoxygenase positive cells co-immunostaining for activated eosinophils (EG2) increased following challenge with lysine aspirin in five ASA individuals and in only one non-ASA subject; this difference was significantly different (p<005).
There were no significant changes in the percentage of 5-lipoxygenase positive cells co- 
Discussion
This study shows that 20 minutes after endobronchial challenge with lysine aspirin solution in ASA individuals there was a significant reduction in the number of mast cells and an increase in the number of activated eosinophils that was not observed in the non-ASA subjects. There is no previous study reporting endobronchial lysine aspirin challenge in aspirin sensitive patients. The timing of the biopsy was determined by the maximal bronchoconstrictor reaction after inhalation of lysine aspirin solution which normally occurs at the same time following challenge. We used the concentration of lysine aspirin for endobronchial challenge in each ASA individual which had already been found to cause a 20% reduction in FEVy when inhaled (the threshold concentration) by the same subject. For the non-ASA subjects the highest concentration of 25 mg/ml was used. We reasoned that the total dose in 20 ,ul applied locally via the bronchoscope was probably substantially greater than the dose which would have deposited at the same location following nebulised inhalation of the same concentration of lysine aspirin solution. The application of higher concentrations of lysine aspirin locally may have induced more profound changes in inflammatory cell populations.
We have used well characterised antibodies for the definition of different inflammatory cells by immunohistochemistry. The 5-lipoxygenase antibody used in the study was raised against purified human leucocyte 5-lipoxygenase and its specificity is indicated by immunoblot recognition of both rat and human leucocyte 5- antibody.'7 Mast cells were identified using an antibody against tryptase, clone AA1, which is a commercially available mouse monoclonal product and recognises mast cell tryptase specifically in the concentrations used in this study.
It was surprising to find that there was a decrease in the number of cells staining with the anti-tryptase antibody following lysine aspirin provocation, because previous work in allergen challenge in vitro has indicated that mast cell degranulation is incomplete and that there should still be substantial tryptase left within the cell. However, no previously published study has reported on the mast cell appearances using the antibody AA1 after either in vivo allergen or aspirin challenges. Furthermore, mast cell tryptase is a water soluble complex, and because cryosections were used in this study, it is possible that during the immunostaining procedure tryptase from degranulated mast cells may have washed away. Thus, the apparent decrease in mast cell numbers found in this study can be explained by the presence of degranulated "phantom" mast cells.
There are several possible explanations for the apparent decrease in mast cell numbers other than substantial degranulation. These include the possibility that the ability to detect mast cells in some of the samples failed for technical reasons. This seems unlikely because it only occurred in ASA individuals after lysine aspirin challenge and there was no significant change in the non-ASA subjects. The results may be explained by the migration of mast cells out of the subepithelium after challenge. However, the time between biopsies was too short for this to have occurred and therefore this possibility also seems unlikely. Finally, lysine aspirin challenge in ASA patients may have produced an element ofmucosal oedema which would result in a decrease in the density of all cells counted in the biopsy samples taken after the challenge. However, the numbers of most of the cells did not change and, indeed, the numbers ofEG2 positive eosinophils increased. Therefore, the most likely explanation for our results is that there was considerable localised mast cell degranulation.
There is substantial evidence from the literature to support the concept for mast 
